Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-1387 + Toripalimab in advanced solid tumors
NCT04284488Phase 2Terminated
- Sponsor
- Ascentage Pharma
- Start
- Apr 2020
- Primary completion
- Nov 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of dasminapant in solid tumor (advanced stage), colorectal cancer (CRC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer (NSCLC), sponsored by Ascentage Pharma. Started Apr 2020; status: terminated.
02
Drugs
dasminapant
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)nasopharyngeal carcinoma (NPC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04284488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04284488.